Intellipharmaceutics International Inc. (NASDAQ:IPCI) Short Interest Update

Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) was the recipient of a large decrease in short interest in September. As of September 29th, there was short interest totalling 1,239,442 shares, a decrease of 57.7% from the September 15th total of 2,932,911 shares. Based on an average trading volume of 476,058 shares, the short-interest ratio is presently 2.6 days. Approximately 5.1% of the company’s stock are sold short.

An institutional investor recently raised its position in Intellipharmaceutics International stock. Argent Trust Co increased its holdings in Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) by 52.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,693 shares of the company’s stock after buying an additional 20,556 shares during the period. Argent Trust Co owned about 0.20% of Intellipharmaceutics International worth $125,000 as of its most recent filing with the Securities & Exchange Commission. 3.47% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently issued reports on IPCI. Maxim Group reissued a “buy” rating and issued a $6.00 target price on shares of Intellipharmaceutics International in a research report on Friday, June 30th. Zacks Investment Research lowered Intellipharmaceutics International from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. ValuEngine lowered Intellipharmaceutics International from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Mackie raised Intellipharmaceutics International to a “hold” rating and raised their price objective for the company from $1.00 to $3.10 in a research report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $2.37.

Intellipharmaceutics International (IPCI) opened at 0.91 on Friday. The company’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.65. The company’s market cap is $28.28 million. Intellipharmaceutics International has a 52-week low of $0.81 and a 52-week high of $3.35.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at

Intellipharmaceutics International Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with's FREE daily email newsletter.

Leave a Reply